JP2011516606A - 様々な治療指標に必要な血漿プロゲステロン濃度を得るための方法および医薬組成物 - Google Patents

様々な治療指標に必要な血漿プロゲステロン濃度を得るための方法および医薬組成物 Download PDF

Info

Publication number
JP2011516606A
JP2011516606A JP2011504940A JP2011504940A JP2011516606A JP 2011516606 A JP2011516606 A JP 2011516606A JP 2011504940 A JP2011504940 A JP 2011504940A JP 2011504940 A JP2011504940 A JP 2011504940A JP 2011516606 A JP2011516606 A JP 2011516606A
Authority
JP
Japan
Prior art keywords
progesterone
concentration
injectable
plasma
particles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011504940A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011516606A5 (enExample
Inventor
ヴィルボエフ，ジョン クロード サヴォワール
ウリベ，ホアン アンヘレス
ヘスース フランシスコ ドセ，マリア テレサ デ
ギベス ロペス レナ，アウレリオ デ
デ レオン，ホアン ラモン マルティネス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Posi Visionary Solutions LLP
Original Assignee
Posi Visionary Solutions LLP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Posi Visionary Solutions LLP filed Critical Posi Visionary Solutions LLP
Publication of JP2011516606A publication Critical patent/JP2011516606A/ja
Publication of JP2011516606A5 publication Critical patent/JP2011516606A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dermatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2011504940A 2008-04-14 2008-04-14 様々な治療指標に必要な血漿プロゲステロン濃度を得るための方法および医薬組成物 Pending JP2011516606A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/MX2008/000051 WO2009128692A1 (es) 2008-04-14 2008-04-14 Método y composición farmacéutica para lograr niveles plasmáticos de progesterona requeridos para diferentes indicaciones terapéuticas

Publications (2)

Publication Number Publication Date
JP2011516606A true JP2011516606A (ja) 2011-05-26
JP2011516606A5 JP2011516606A5 (enExample) 2012-04-12

Family

ID=41199287

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011504940A Pending JP2011516606A (ja) 2008-04-14 2008-04-14 様々な治療指標に必要な血漿プロゲステロン濃度を得るための方法および医薬組成物

Country Status (8)

Country Link
US (1) US20110104289A1 (enExample)
EP (1) EP2272519A4 (enExample)
JP (1) JP2011516606A (enExample)
CN (1) CN102056611A (enExample)
BR (1) BRPI0822165A2 (enExample)
CA (1) CA2721509A1 (enExample)
IL (1) IL208723A0 (enExample)
WO (1) WO2009128692A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021501343A (ja) * 2017-10-30 2021-01-14 カーメンティクス・プロプライエタリー・リミテッド 早産のバイオマーカー

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014012444B1 (pt) 2011-11-23 2021-12-14 Therapeuticsmd, Inc Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
AU2015296609A1 (en) 2014-07-29 2016-12-22 Therapeuticsmd, Inc. Transdermal cream
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
KR20180126582A (ko) 2016-04-01 2018-11-27 쎄러퓨틱스엠디, 인코퍼레이티드 스테로이드 호르몬 약제학적 조성물
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0474117A (ja) * 1990-07-16 1992-03-09 Kokuritsu Eisei Shikenjo 新規なマイクロスフェア
JPH05507694A (ja) * 1990-06-14 1993-11-04 アプリカシオネス　ファルマシューティカス，ソシエダド　アノニマ　デ　カピタル　バリアブレ 注射可能な医薬組成物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2663224B1 (fr) 1990-06-14 1995-01-20 Applicationes Farmaceuticas Sa Forme galenique parenterale.
US6287693B1 (en) * 1998-02-25 2001-09-11 John Claude Savoir Stable shaped particles of crystalline organic compounds
US6544553B1 (en) * 1999-12-28 2003-04-08 Watson Pharmaceuticals, Inc. Dosage forms and methods for oral delivery of progesterone
ATE454885T1 (de) * 2003-06-13 2010-01-15 Skendi Finance Ltd Mikrosphären von estradiol und cholesterol

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05507694A (ja) * 1990-06-14 1993-11-04 アプリカシオネス　ファルマシューティカス，ソシエダド　アノニマ　デ　カピタル　バリアブレ 注射可能な医薬組成物
JPH0474117A (ja) * 1990-07-16 1992-03-09 Kokuritsu Eisei Shikenjo 新規なマイクロスフェア

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6013011903; Ａｃｔａ　Ｍｅｄｉｃａ　Ｇｒｕｐｏ　Ａｎｇｅｌｅｓ ６，１, 200803, ８-１３ *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021501343A (ja) * 2017-10-30 2021-01-14 カーメンティクス・プロプライエタリー・リミテッド 早産のバイオマーカー

Also Published As

Publication number Publication date
CN102056611A (zh) 2011-05-11
US20110104289A1 (en) 2011-05-05
EP2272519A4 (en) 2011-04-27
BRPI0822165A2 (pt) 2015-06-16
IL208723A0 (en) 2010-12-30
CA2721509A1 (en) 2009-10-22
WO2009128692A1 (es) 2009-10-22
EP2272519A1 (en) 2011-01-12

Similar Documents

Publication Publication Date Title
JP2011516606A (ja) 様々な治療指標に必要な血漿プロゲステロン濃度を得るための方法および医薬組成物
JP6902583B2 (ja) 頭痛治療用の鼻腔内ｄｈｅ
US20100086599A1 (en) Oral modified release formulations
RU2314810C2 (ru) Способ лечения с использованием лекарственных форм, содержащих фармацевтические композиции 5,8,14-триазатетрацикло[10.3.1.0 (2,11).0(4,9)] гексадека-2( 11),3,5,7,9-пентаена
JP2008535867A (ja) Ｃｎｓ関連疾患の治療のための方法及び組成物
US20080038350A1 (en) Low-dosage peroral medication for contraception containing crystalline dienogest and ethinyl estradiol
AU2016282863B2 (en) Drospirenone-based contraceptive for a female patient affected with excess weight
HUP0303313A2 (hu) Transzdermális gyógyszerkészítmények
HUE033590T2 (hu) Esztetrol alkalmazása sürgõsségi fogamzásgátlóként
EP2790688B1 (en) A multiphasic contraceptive regimen for an oral formulation of progestin and estrogen
CA2893959A1 (en) Pharmaceutical compositions
JPH11514650A (ja) 治療用シスプラチン（ｃｄｄｐ）のための改良された方法及び組成物
CA3144713A1 (en) Pharmaeutical composition comprising ensifentrine
JP2011503075A (ja) エポチロンまたはエポチロン誘導体誘発下痢を処置するためのコルチコステロイド
US20120040970A1 (en) Intranasal delivery system for dantrolene
JP2003510336A (ja) 虚血性損傷においてのエストロゲンのエナンチオマーを用いる細胞保護の方法
US20060100180A1 (en) Composition containing an androgenous 11b-halogen steroid and a progestational hormone, and male contraceptive based on said composition
TW200529861A (en) Methods and reagents for the treatment of inflammatory disorders
US20090023693A1 (en) New drospirenone/17beta-estradiol regimen, pharmaceutical combination product and kit for performing this regimen
IL277802B1 (en) Sustained release injectable composition of letrozole
HUP0300128A2 (en) Male contraceptive composition comprising norethisterone and its use
Paoletti et al. Comparison of pharmacokinetic profiles of a 17β-estradiol gel 0.6 mg/g (Gelestra) with a transdermal delivery system (Estraderm TTS 50) in postmenopausal women at steady state
TW200817012A (en) Peroral medicament form for contraception
MX2010011296A (es) Metodo y composicion farmaceutica para lograr niveles plasmaticos de progesterona requeridos para diferentes indicaciones terapeuticas.
JPWO2020247627A5 (enExample)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110413

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110413

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120217

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130319

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20131210